Skip to main content
SpringerLink
Log in

Allgemeines

  • Chapter
  • First Online:
Medikamentöse Tumortherapie in der Dermato-Onkologie

  • 1697 Accesses

Zusammenfassung

Die medikamentöse Tumortherapie umfasst die Anwendung und Überwachung der medikamentösen Therapie von Tumorerkrankungen, einschließlich supportiver Maßnahmen und der Therapie auftretender Komplikationen, und sollte nur von darin ausgebildeten und erfahrenen Ärztinnen und Ärzten durchgeführt werden. Vor jeder Therapie sollen der zu erwartende Nutzen, der Ablauf der Therapie, die Risiken und die Nebenwirkungen ausführlich mit dem Patienten besprochen werden. Ebenso soll der Patient informiert sein über mögliche Komplikationen und das Vorgehen bei Komplikationen. Der Patient muss instruiert werden, seine Symptome frühzeitig zu äußern.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Besser MJ, Shapira-Frommer R, Treves AJ et al. (2010) Clinical: Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clin Cancer Res 16(9):2646–2655

    Article  PubMed  CAS  Google Scholar 

  • Buzzacco DM, Abdel-Rahman MH, Park S, Davidorf F, Olencki T, Cebulla CM (2012) Long-term survivors with metastatic uveal melanoma. Open Ophthalmol J 6:49–53

    Article  PubMed  Google Scholar 

  • Curiel TJ (2013) Cancer Immunotherapy: Paradigms, Practice and Promise. Springer, Berlin Heidelberg New York

    Book  Google Scholar 

  • Da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, Giuliani R, Pignatti F (2013) The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer (in press)

    Google Scholar 

  • Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, Bedognetti D, Queirolo P, Morosini P, Perrone T, Bajetta E, Anichini A (2010) Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 16(23):5862–72

    Article  PubMed  CAS  Google Scholar 

  • Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Salès F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A (2012) Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48(2):218–25

    Article  PubMed  CAS  Google Scholar 

  • Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O’Dwyer PJ, Ratain MJ (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.Br J Cancer 95(5):581–6

    Article  PubMed  CAS  Google Scholar 

  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version1.1). Eur J Cancer 45:228–47; http://www.recist.com/recist-in-practice/01.html)

    Google Scholar 

  • Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L (2005) Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 52(5):847–53

    Article  PubMed  Google Scholar 

  • Gitay-Goren H, Halaban R, Neufeld G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun. 1993 Feb 15;190(3):702-8.Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70

    Google Scholar 

  • Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, Wei L, Walker MJ, Chen HX, Kendra K, Carson WE 3rd. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother. 2011 Jul-Aug; 34(6):509–15

    Google Scholar 

  • Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM, Clark BL, Rubin MS, Trent DF, Burris HA 3rd. (2010) Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 116(17):4122–9

    Article  PubMed  CAS  Google Scholar 

  • Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70

    Article  PubMed  CAS  Google Scholar 

  • Hartmann A, Kunz M, Köstlin S, Gillitzer R, Toksoy A, Bröcker EB, Klein CE (1999) Hypoxia-induced upregulation of angiogenin in human malignant melanoma. Cancer Research 59: 1578–1583

    PubMed  CAS  Google Scholar 

  • Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O’Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27: 2823–2830

    Article  PubMed  CAS  Google Scholar 

  • Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R (1987) Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer. 2000 Oct 15;89(8):1835-44.Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H. Biology of tumor progression in human melanocytes. Lab Invest 56 :461–474

    Google Scholar 

  • Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, Espinosa E, Hauschild A, Quirt I, Robert C, Schadendorf D (2009) Small molecules and targeted therapies in distant metastatic disease. Ann Oncol Suppl 6:vi35–40

    Google Scholar 

  • Hiddemann W, Bartram CR (2010) Die Onkologie. 2. Auflage. Springer, Berlin Heidelberg New York

    Book  Google Scholar 

  • Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O’Day SJ (2012) BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30(1):34–41

    Article  PubMed  CAS  Google Scholar 

  • Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT 3rd, Geoffroy FJ, Gross HM, Cohen PA, Jaslowski AJ, Kosel ML, Markovic SN (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119(3):586–92

    Article  PubMed  CAS  Google Scholar 

  • Kunz M, Hartmann A (2002) Angiogenesis – Antiangiogenesis. Significance for tumor growth and metastasis. Hautarzt 53: 373–384

    Article  PubMed  CAS  Google Scholar 

  • Kurzen H, Schmitt S, Näher H, Möhler T (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14(7):515–22

    Article  PubMed  CAS  Google Scholar 

  • Lansiaux A, Salingue S, Dewitte A, Clisant S, Penel N. Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy. Invest New Drugs. 2012 Feb; 30(1):403–4

    Google Scholar 

  • Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12(12):1005–16

    Article  PubMed  Google Scholar 

  • Markovic A, Chung CH (2012) Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert Rev Anticancer Ther 12(9):1149–59

    Article  PubMed  CAS  Google Scholar 

  • Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–14

    Article  PubMed  CAS  Google Scholar 

  • Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317(17):1098

    PubMed  CAS  Google Scholar 

  • Murray A, Little SJ, Stanley P, Maraveyas A, Cawkwell L (2010) Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.Oncol Rep 24(4):1049–58

    PubMed  CAS  Google Scholar 

  • Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    Article  PubMed  CAS  Google Scholar 

  • O’Regan KN, Jagannathan JP, Ramaiya N, Hodi FS (2011) Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol 197(2):W241–6

    Article  PubMed  Google Scholar 

  • Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7(8):455–65

    Article  PubMed  Google Scholar 

  • Preiss J, Dornoff W, Hagmann FG, Schmieder A (2012) Taschenbuch Onkologie 2010/2011. 15. Auflage. Zuckschwerdt, Germering

    Google Scholar 

  • Reichle A, Bross K, Vogt T, Bataille F, Wild P, Berand A, Krause SW, Andreesen R. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.Cancer. 2004 Nov 15; 101(10):2247–56

    Google Scholar 

  • Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Brolli C, Selva M, Scarpi E, Valmorri L, Nicoletti SV, Guidoboni M, Riccobon A, Ridolfi R (2011) Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. Melanoma Res 21(6):524–9

    Article  PubMed  CAS  Google Scholar 

  • Schuler G, Auböck J, Huber H (1984) [Bleomycin-induced linear hyperpigmentation]. Hautarzt 35(7):383–6

    PubMed  CAS  Google Scholar 

  • Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Röder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den Driesch P, Knop J, Bröcker EB, Enk A, Kämpgen E, Schuler G (2000) Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 165(6):3492–6

    PubMed  CAS  Google Scholar 

  • Schuler-Thurner B, Schuler G (2005) Vaccination therapy of melanoma. J Dtsch Dermatol Ges 3(8):630–45

    Article  PubMed  Google Scholar 

  • Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G (2004) Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol 172(2):1304–10

    PubMed  CAS  Google Scholar 

  • Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119–27

    Article  PubMed  CAS  Google Scholar 

  • Sekulic A, Mangold AR, Northfelt DW, Lorusso PM (2013) Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol (in press)

    Google Scholar 

  • Spenny ML, Walford J, Werchniak AE, Beltrani V, Brennick JB, Storm CA, Perry AE, Chapman MS (2007) Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 79(2):149–52

    PubMed  Google Scholar 

  • Steinmann A, Funk JO, Schuler G, von den Driesch P (2000) Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 43(3):555–6

    PubMed  CAS  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–16

    Article  PubMed  CAS  Google Scholar 

  • von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schläppi M, Moch H, Schraml PH, Mjhic-Probst D, Mamot C, Schönewolf N, Dummer R; Swiss Group for Clinical Cancer Research (SAKK) (2012) First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 23(2):531–6

    Article  Google Scholar 

  • Westermark B, Johnsson A, Paulsson Y, Betsholtz C, Heldin CH, Herlyn M, Rodeck U, Koprowski H (1986) Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci USA 83(19):7197–200

    Article  PubMed  CAS  Google Scholar 

  • Algorithmus für Ipilimumab-Nebenwirkungen (Faltblatt und App): http://www.yervoy.de/fachkreis_informationsmaterialien-fuer-fachkreise.html

  • Fragen der Reproduktion in Zusammenhang mit medikamentöser Tumortherapie: www.fertiprotekt.de

  • Kalkulation der Körperoberfläche: http://www.esmo.org/fileadmin/practice/bodymass.php

  • Nebenwirkungen nach CTCAE: http://evs.nci.nih.gov/ftp1/CTCAE/About.html

  • Seltene Krankheiten: http://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials_Simple.php?lng=DE & LnkId=17954 & Typ=Pat

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum Erlangen, Hautklinik, Ulmenweg 18, 91054, Erlangen, Deutschland

    Lucie Heinzerling, Anke Hartmann & Gerold Schuler

  2. Privatpraxis für Dermatologie und Ästhetische Medizin, Rzany und Hund, Ku’damm 183, 10707, Berlin, Deutschland

    Martina Hund

Authors
  1. Lucie Heinzerling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anke Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martina Hund
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gerold Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucie Heinzerling .

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Heinzerling, L., Hartmann, A., Hund, M., Schuler, G. (2014). Allgemeines. In: Medikamentöse Tumortherapie in der Dermato-Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-24837-5_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-24837-5_1

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-24836-8

  • Online ISBN: 978-3-642-24837-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation